Veterinary Medicines

PROGRAM Plus

Authorised
  • Milbemycin oxime
  • Lufenuron
Download as PDF

Product identification

Medicine name:
PROGRAM Plus
INTERCEPTOR PLUS compresse rivestite da 2,3mg/46 mg per cani
Active substance:
  • Milbemycin oxime
  • Lufenuron
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    2.30
    milligram(s)
    /
    1.00
    Tablet
  • Lufenuron
    46.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:
  • Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton
  • Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Elanco France S.A.S.
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • 102569
Date of authorisation status change:
Reference member state:
  • Italy
Procedure number:
  • IT/V/0106/001
Concerned member states:
  • Austria
  • Germany
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 14/02/2022
Download